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Letters to the Editorveno-venous support in cases of right
ventricular failure. Although veno-
venous support is generally not success-
ful in cases of right ventricular failure,
the patient in our series was seen with
severe pulmonary hypertension and
a large atrial septal defect with a right-
to-left shunt. Flow from the cannula
was therefore preferentially shunted
across the atrial septal defect, resulting
in functional veno-arterial support.
We also commend their group for
the use of the Avalon dual-lumen can-
nula (Avalon Laboratories, LLC, Ran-
cho Dominguez, Calif) for patients
with a body surface area greater than
2.0. In our initial experience, we
were concerned that high enough
flow rates to fully oxygenate these pa-
tients would not be achievable. We
have subsequently, however, used the
Avalon cannula with surprising suc-
cess in patients with a body surface
area greater than 2.0.
In reply to the comment regarding
range of gas exchange rates in this se-
ries, we too generally recorded rates
between 200 mL/min and 300 mL/
min. Only a single time point was
found to have a rate greater than 500
mL/min, and this value may simply
represent laboratory error.
This remains an exciting time in the
evolution of care for patients with
severe lung injury, and further study
of the use of ambulatory extracorporeal
membraneoxygenation is still required.
Jose P. Garcia, MD
Zachary N. Kon, MD
Bartley P. Griffith, MD
Division of Cardiac Surgery
Department of Surgery
University of Maryland School of
Medicine
Baltimore, Md
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LOBECTOMY
To the Editor:
We read with interest the article en-
titled, ‘‘Video-Assisted Thoracoscopic284 The Journal of Thoracic and CSurgery (VATS) Lobectomy: Cata-
strophic Intraoperative Complica-
tions,’’ by Flores and colleagues1 in
the December 2011 issue of The Jour-
nal of Thoracic and Cardiovascular
Surgery. We are interested in their ex-
perience and would like to make
some comments.
For patient 1 among the 12 cases
they described, Flores and colleagues1
said that the posterior ascending
branch of the pulmonary artery had
calcified lymph nodes that required
dissection. Subsequently, the pulmo-
nary artery was damaged irreparably,
and intrapericardial proximal arterial
control was needed with a thoracot-
omy. As a result, a planned right upper
lobectomy was eventually converted
into a pneumonectomy. We do not
know the details of the manipulation,
because Flores and colleagues1 did
not describe it further.
We would like to recommend in
such cases the ‘‘en masse lobectomy.’’
Originally, enmasse hilarmanagement
was the main technique used in lobec-
tomy, because surgeonswarnedagainst
hilar dissection and individual ligation
for fear of spreading infection by open-
ing inflamed tissue planes.2 Times
have changed, however, and individual
hilar management has become the
standard procedure in modern lobec-
tomy. Nevertheless, some authors3,4
still report that en masse lobectomy is
useful under certain conditions.
From an oncologic perspective,
care should be taken when handling
malignant lung diseases because of
the potential for lymph node metasta-
sis. If no lymph node metastasis is de-
tected preoperatively, and there are
inflammatory adhesions to the pulmo-
nary artery, we do not think that dis-
section is required. Even if this is not
the case, we think that an octogenarian
would welcome an en masse lobec-
tomy as a thorough pneumonectomy.
If no calcifications are found, a me-
chanical stapler could be applied to
the divided root of the right upper
lobe, as is done with simultaneously
stapled lobectomies.5ardiovascular Surgery c July 2012We believe that this technique
might help to avoid catastrophic intra-
operative complications. Thus, with
an understanding of what has taken
place in the past, it should be possible
to reshape the present and future.
Mitsuhiro Kamiyoshihara, MD, PhD
Hitoshi Igai, MD, PhD
Takashi Ibe, MD, PhD
Department of General Thoracic
Surgery
Maebashi Red Cross Hospital
Maebashi, Japan
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With regard to our article, ‘‘Video-
Assisted Thoracoscopic Surgery
(VATS) Lobectomy: Catastrophic In-
traoperative Complications,’’1 I agree
with Kamiyoshihara and associates
that enmasse lobectomy (tourniquet lo-
bectomy) is a useful tool in the thoracic
surgeon’s armamentarium. This proce-
dure has the potential, however, to leave
N1 nodal disease behind in patients
with lung cancer. The key is to identify
the potentially dangerous situation be-
fore starting the dissection.Heavily cal-
cified lymph nodes and an artery that is
inseparable from the bronchus should
be clues to avoid further dissection,
and a tourniquet lobectomy may prove
to be a very useful alternative. Never-
theless, tourniquet lobectomy does not
Letters to the Editorfollow surgical oncologic principles
and should be regarded as a bailout
procedure and used judiciously.
Raja M. Flores, MD
Division of Thoracic Surgery
Mount Sinai School of Medicine
New York, NYReference
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HETEROGRAFT VALVE
CALCIFICATION PLEASE
STAND UP?
To the Editor:
Sinha and colleagues1 are not the
first to implicate glutaraldehyde as
a culprit for tissue valve calcification.
Although they are to be commended
for their careful methods and the sug-
gestion that glutaraldehyde concentra-
tion and exposure times appear to
correlate with the degree of calcifica-
tion, they unfortunately failed to reach
far enough back into the literature to
recognize that most of their questions
had already been answered by others.2
A closer look at the literature might
also have led these researchers to ar-
rive at a different conclusion; that is,
calcific degeneration of heterograft
tissues is primarily an immunologic
phenomenon.
Alain Carpentier and his wife So-
phie, a biochemist, are given credit
for the introduction of aldehyde chem-
istry to themodernmanufacture of het-
erograft tissue valves.3 At the time,
they did not advance an argument
that aldehyde preservation rendered
heterograft tissues nonimmunogenic.
That perception belongs to perspica-
cious marketing departments within
the tissue valve industry. The observa-
tion that calcific degeneration of het-
erograft valves is an age-relatedThe Journalphenomenon was an early and impor-
tant clue to the problem of tissue valve
durability.4 These issues notwithstand-
ing, the Carpentiers’ discovery had al-
ready spawned the multibillion dollar
industry of heterograft tissue heart
valves.
More than30years ago, Salgaller and
Bajpai5 detected both cellular and
humoral immune responses to
glutaraldehyde-treated and untreated
bovine pericardium. Their data pro-
vided the first real proof that
glutaraldehyde-preserved heterograft
tissues are not biologically inert and re-
main antigenic. The association be-
tween a smoldering immune response
and tissue valve durability was never
widely recognized,however, andglutar-
aldehyde continued to be the presumed
cause of heterograft calcification, lead-
ing researchers and companies to search
for new tissue treatments designed to re-
tard calcification.
Love and associates6 first described
the successful use of autologous peri-
cardium briefly treated in 0.6%
glutaraldehyde for use as a stent-
mounted valve replacement. Since
this introduction, multiple investiga-
tors have reported wide success with
the use of autologous pericardium
briefly treated in 0.6% glutaraldehyde
for the replacement of semilunar heart
valves7 and the repair of damaged and
shortened mitral valve leaflets.8 All
these techniques have proved durable,
and in none of the published experi-
ences, including those with pediatric
or very young patients, has calcific
degeneration been considered
a limitation.
The more than 20-year clinical ex-
perience with autologous pericardium
briefly immersed in glutaraldehyde
and used for valve reconstruction
should finally dispel any perception
that aldehydes are directly responsible
for calcific degeneration of tissue
valves.
Charles S. Love, BA
Spot On Medical, LLC
Santa Barbara, Califof Thoracic and Cardiovascular SurgeReferences
1. Sinha P, Zurakowski D, Kumar TK, He D, Rossi C,
Jonas RA. Effects of glutaraldehyde concentration,
pretreatment time, and type of tissue (porcine ver-
sus bovine) on postimplantation calcification.
J Thorac Cardiovasc Surg. 2012;143:224-7.
2. Fishbein MC, Levy RJ, Ferrans VJ, Dearden LC,
Nashef A, Goodman AP, et al. Calcifications of car-
diac valve bioprostheses. Biochemical, histologic,
and ultrastructural observations in a subcutaneous
implantation model system. J Thorac Cardiovasc
Surg. 1982;83:602-9.
3. Carpentier A. From valvular xenograft to valvular
bioprosthesis (1965-1977). Med Instrum. 1977;11:
98-101.
4. Dunn JM. Porcine valve durability in children. Ann
Thorac Surg. 1981;32:357-68.
5. Salgaller ML, Bajpai PK. Immunogenicity of
glutaraldehyde-treated bovine pericardial tissue xe-
nografts in rabbits. J Biomed Mater Res. 1985;19:
1-12.
6. Love JW, Calvin JH, Phelan RF, Love CS. Rapid in-
traoperative fabrication of an autologous tissue
heart valve: a new technique. In: Bodnar E, Ya-
coub M, eds. Proceedings of the Third International
Symposium on Cardiac Bioprostheses. New York:
Yorke Medical; 1986:691-8.
7. Chan KM, Rahman-Haley S, Mittal TK, Gavino JA,
Dreyfus GD. Truly stentless autologous pericardial
aortic valve replacement: an alternative to standard
aortic valve replacement. J Thorac Cardiovasc
Surg. 2011;141:276-83.
8. Chauvaud S, Jebara V, Chachques JC, el Asmar B,
Mihaileanu S, Perier P, et al. Valve extension with
glutaraldehyde-preserved autologous pericardium.
Results in mitral valve repair. J Thorac Cardiovasc
Surg. 1991;102:171-8.
doi:10.1016/j.jtcvs.2012.01.085Reply to the Editor:
We thank Mr Love for responding
to our article1 and for emphasizing
the importance of immune mecha-
nisms in heterograft calcification. We
are in agreement that aldehyde treat-
ment is just one of several factors
that can exacerbate calcification of
implanted tissues. In the clinical set-
ting of pediatric cardiac surgery,
where autologous pericardium is often
used and immune mechanisms are
presumably not so important, how-
ever, it is the factor that can be most
readily modified. Unfortunately, our
animal model was not suited to autol-
ogous pericardium implantation.
We strongly disagree with Mr
Love’s assertion that calcific degener-
ation never occurs in the pediatric
setting when glutaraldehyde-treated
autologous pericardium is used forry c Volume 144, Number 1 285
